All In Biotech

Drug Trial Radar · NCT02167893

Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"

Leuprorelin Acetate SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"

Last checked: Nov 19, 2026Latest source record: Mar 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

11,288

Actual

Start

Oct 2005

Primary completion

Dec 2010

Study completion Dec 2010

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jun 19, 2014

More drug trials from this sponsor

Design

Study type
Observational
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this survey is designed to evaluate the efficacy and safety of long-term use (96 weeks) of leuprorelin acetate SR 11.25 milligram (mg) injection kit (Leuplin SR 11.25 mg injection kit) in prostate cancer participants in daily medical practice.

Conditions

  • Prostate Cancer

Interventions

  • Leuprorelin acetateDrug

    Leuprorelin acetate SR 11.25 mg injection kit

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting One or More Adverse Drug ReactionsTime frame: Baseline up to Week 96
  2. Number of Participants Reporting One or More Serious Adverse Drug ReactionsTime frame: Baseline up to Week 96

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.